An interventional study of Alpha MSH assay in Advanced Dry Macular Degeneration, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-22.
Sponsored by Duke University · Not applicable, Interventional, and Diagnostic
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.
A small amount (0.1 mL) of aqueous humor would be removed from the study eye in the clinic setting. This sample will be processed and then sent off for measurement of alpha MSH levels.
1,459 studies on the registry are indexed under Macular Degeneration; 238 are open to participants now.
This study's enrollment of 54 is close to the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →Duke University is the lead sponsor of 2,063 studies on the registry; 273 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Alpha MSH assay
Assay to detect levels of alpha MSH in intraocular fluid.
Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay
Time frame: 2 hours
| Milestone | Advanced Dry Macular Degeneration |
|---|---|
| Started | 54 |
| Completed | 54 |
| Not completed | 0 |
No measurements were reported for this outcome.
Collected over 1 visit, up to 2 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Advanced Dry Macular Degeneration | 0/54 (0%) | 0/54 (0%) | 0/54 (0%) |
| Age, Continuous(years) | Advanced Dry Macular Degeneration |
|---|---|
| Mean | 67.9 ± 10.9 |
| Sex: Female, Male(Participants) | Advanced Dry Macular Degeneration |
|---|---|
| Female | 34 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Advanced Dry Macular Degeneration |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 52 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Advanced Dry Macular Degeneration |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 45 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(Participants) | Advanced Dry Macular Degeneration |
|---|---|
| United States | 54 |
Plan to share: No
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.